mAbxience
Chemicals & Related Products · Switzerland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Via Maggio 1, Lugano, Ticino, 6900, Swit...Phone Number
+41 919731423Website
www.mabxience.comRevenue
$59.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About mAbxience
mAbxience is a biopharmaceutical company recognized as a global leader in the development of biosimilars. They offer tailored Contract Development and Manufacturing Organization (CDMO) solutions, emphasizing quality, agility, and flexibility in manufacturing. The company is dedicated to improving patient access to treatments worldwide through their expertise in biologics and biosimilars. With over a decade of experience, mAbxience provides end-to-end solutions to meet diverse manufacturing needs, from research to commercial batches.Explore more
mAbxience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is mAbxience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on mAbxience recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when mAbxience launches new products
Check out if mAbxience is spiking on competitors!
Check if mAbxience has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at mAbxience
Funding: Get notified immidiatlly once mAbxience has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
mAbxience, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if mAbxience had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
mAbxience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
mAbxience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about mAbxience.
mAbxience Tech Stack
A closer look at the technologies used by mAbxience
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Training, Sales, Logistics / Supply Chain, Pharmaceuticals, Clinical Operations, Field Marketing, Manufacturing Operations, Operations
Person-Based
Person-Based
Person-Based
Promotion
Executive Move
Executive Moves, Promotion
mAbxience News & Media
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a biosimilar referencing Prolia®, and Oziltus™ (denosumab-mobz), a biosimilar referencing XGEVA®.mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars. The project...mAbxience Announces European Commission Approval of Denosumab Biosimilars
MADRID, July 2, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This approval follows a positive...Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding mAbxience
Sign Up For FreeTo access detailed company insights
mAbxience is a biopharmaceutical company recognized as a global leader in the development of biosimilars. They offer tailored Contract Development and Manufacturing Organization (CDMO) solutions, emphasizing quality, agility, and flexibility in manufacturing. The company is dedicated to improving patient access to treatments worldwide through their... Read More
